US2008206353A1PendingUtilityA1
Formulations And Treatments For Trichology
Est. expiryDec 24, 2024(expired)· nominal 20-yr term from priority
Inventors:Jon Phillips
A61P 9/00A61P 3/00A61P 3/02A61P 17/14A61P 17/00A61K 8/9794A61K 8/9771A61K 8/9789A61K 8/9741A61K 36/48A61K 8/27A61Q 7/00A61K 31/10A61K 8/44A61K 2800/58A61K 8/58A61K 36/889A61K 36/736A61K 36/11A61K 8/4906A61K 36/258A61K 8/986A61K 36/704A61K 8/466A61K 36/16A61K 31/56A61K 8/63A61K 35/20
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
a formulation for trichological treatment of a patient including, in a dosage in the range of 3 g to 8 g: phytosterols in the range of 200 mg to 2500 mg; the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600 mg; methylsulfonylmethane in the range of 500 mg to 2000 mg; and bovine colostrum in the range of 500 m to 2000 m.
Claims
exact text as granted — not AI-modified1 - 61 . (canceled)
62 . A formulation for trichological treatment including:
a 5-alpha reductase production inhibitor selected from one or more phytosterols as equivalents to beta-sitosterol; methylsulfonylmethane; extract from the herbal variety Polygonum multiflorum; levo-arginine; colostrum; and Gingko biloba.
63 . The formulation for trichological treatment according to claim 62 , wherein the formulation includes zinc amino acid chelate.
64 . The formulation for trichological treatment according to claim 62 or claim 63 , wherein the formulation includes any one or more extracts from the herbal varieties:
Polygonum multiflorum; Gingko biloba; Equisetum arvense; Panax quinquefolium.
65 . The formulation for trichological treatment according to claim 64 , wherein the formulation includes any one or more of the following components:
one or more soy isoflavones; levo-arginine; inositol; niacin; biotin; calcium pantothenate; dextro-alpha-tocopherol; Pyridoxine hydrochloride;
66 . The formulation for trichological treatment according to claim 62 , wherein the colostrum is bovine colostrum.
67 . The formulation for trichological treatment according to claim 62 , wherein the 5-alpha reductase production includes extract from Serenoa repens.
68 . The formulation for trichological treatment according claim 62 , and including Pygeum repens.
69 . The formulation for trichological treatment according to claim 62 , and including thiamine.
70 . The formulation for trichological treatment according to claim 62 , and including riboflavin.
71 . A formulation for trichological treatment of a patient including, in a dosage in the range of 3 g to 8 g:
phytosterols as equivalents to beta-sitosterol in the range of 200 mg to 2500 mg; the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600 mg; methylsulfonylmethane in the range of 500 mg to 2000 mg; bovine colostrum in the range of 500 mg to 2000 mg; and the quantitative equivalent of Gingko biloba leaf extract 50:1 in 70% EW in the range of 50 mg to 1000 mg.
72 . A formulation for trichological treatment according to claim 71 , and further including the quantitative equivalent of zinc amino acid chelate 20% in the range of 10 mg to 40 mg.
73 . The formulation for trichological treatment according to claim 71 or claim 72 , and including any one or more of the following components:
arginine in the range of 120 mg to 500 mg; biotin in the range of 0.7 mg to 5 mg; nicotinic acid in the range of 5 mg to 30 mg; calcium pantothenate in the range of 10 mg to 400 mg; pyridoxine hydrochloride in the range of 10 mg to 400 mg; d-a-tocopherol acetate in the range of 200 Hi to 800 IU; and colloidal anhydrous silica in the range of 6O mg to 500 mg.
74 . The formulation for trichological treatment according to claim 71 , and including any one or more of the following components:
the quantitative equivalent of Glycine Max (soy) seed 65:1 in 75% EW in the range of 80 mg to 3250 mg; the quantitative equivalent of Panax quinquefolium root extract 3:1 in 15% EW in the range of 50 mg to 1000 mg; the quantitative equivalent of Equisetum arvense herb extract 4:1 in 100% water in the range of 50 mg to 1000 mg; inositol in the range of 70 mg to 300 mg;
75 . The formulation for trichological treatment according to claim 71 , wherein the phytosterols are in the range of 200 mg to 2500 mg.
76 . The formulation for trichological treatment according to claim 71 , wherein the phytosterols are in the range of 200 mg to 1000 mg.
77 . The formulation for trichological treatment according to claim 71 , wherein the Gingko biloba extract is in the range of 50 mg to 1000 mg.
78 . The formulation for trichological treatment according to claim 71 . wherein the Gingko biloba extract is in the range of 50 mg to 500 mg.
79 . The formulation for trichological treatment according to any one of claim 74 , wherein the Panax quinquefolium root extract is in the range of 50 mg to 1000 mg.
80 . The formulation for trichological treatment according to claim 74 , wherein the Panax quinquefolium root extract is in the range of 50 mg to 500 mg.
81 . The formulation for trichological treatment according to claim 74 , wherein the Equisetum arvense herb extract is in the range of 50 mg to 1000 mg.
82 . The formulation for trichological treatment according to claim 74 , wherein the Equisetum arvense herb extract is in the range of 50 mg to 500 mg.
83 . The formulation for trichological treatment according to claim 71 , wherein the bovine colostrum is in the range of 50 mg to 2000 mg.
84 . The formulation for trichological treatment according to claim 73 , wherein the bovine colostrum is in the range of 500 mg to 1000 mg.
85 . The formulation for trichological treatment according to claim 73 , wherein the biotin is in the range of 0.7 mg to 3 mg.
86 . The formulation for trichological treatment according to claim 73 , wherein the pyridoxine hydrochloride is in the range of 100 mg to 400 mg.
87 . A medicinal formulation for trichological treatment including:
extracts from the herbal varieties: Polygonum multiflorum; Gingko biloba; Equisetum arvense; Panax quinquefolium; methylsulfonylmethane; levo-arginine; a 5-alpha reductase production inhibitor; one or more soy isoflavones; inositol; niacin; biotin; calcium pantothenate; dextro-alpha-tocopherol; pyridoxine hydrochloride; zinc amino acid chelate; and colostrum.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.